A New Transcatheter Aortic Valve Replacement System for Predominant XXXX Implantation of  the  J-Valve and Early Outcome.

@entity1 @entity2478 @entity730 @entity337 @entity472
OBJECTIVES: This study introduces a newly designed transcatheter aortic valve system, the J-Valve system, and evaluates its application in @entity1 with predominant @entity337 without significant valve @entity730 . We also report the early results of one of the first series of transapical implantations of this device and aim to offer guidance on the technical aspects of the procedure. BACKGROUND: Transcatheter aortic valve replacement (TAVR) has been widely used in high-risk @entity1 for surgical aortic valve replacement. However, the majority of the TAVR devices were designed for @entity472 with significant valve @entity730 . METHODS: Six @entity1 with native @entity337 without significant valve @entity730 (age, 61 to 83 years; mean age, 75.50    8.14 years) underwent transapical implantation of the J-Valve prosthesis (JieCheng Medical Technology Co., Ltd., Suzhou, China), a self-expandable porcine valve, in the aortic position at our institution. All @entity1 were considered to be prohibitive or high risk for surgical valve replacement (logistic EuroSCORE [European System for Cardiac Operative Risk Evaluation], 22.15% to 44.44%; mean, 29.32    7.70%) after evaluation by an interdisciplinary heart team. Procedural and clinical outcomes were analyzed. RESULTS: Implantations were successful in all @entity1 . During the follow-up period (from 31 days to 186 days, mean follow-up was 110.00    77.944 days), only 1 @entity1 had trivial prosthetic valve regurgitation, and none of these @entity1 had @entity2478 of more than mild grade. There were no major post-operative complications or mortality during the follow-up. CONCLUSIONS: Our study demonstrated the feasibility of transapical implantation of the J-Valve system in high-risk @entity1 with predominant @entity337 .
